← Leaderboards
Lindsey Blake De Lott
University Of Michigan At Ann Arbor
$2,080,291
Attributed
$2,080,291
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $578.1K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,080,291 · 2
By mechanism
R01$1,042,246 · 1
K23$1,038,045 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Matthias Kretzler$40,447,062
- Yusuke Shiozawa$3,431,923
- Jon-Kar Zubieta$15,880,746
- Steven J. Katz$12,985,075
- Andrew Robert Sas$1,745,841
Others in their field
Other Emerging Leaders on “Perception”
- Rene S. Kahn · Icahn School Of Medicine At Mount Sinai$16,378,315
- Michael P Harms · Washington University$13,645,932
- Ashkan Vaziri · Biosensics, Llc$7,523,853
- Wei Lu · Van Andel Research Institute$7,383,018
- Benjamin E Deverman · Broad Institute, Inc.$6,462,832
- Ganna Kostygina · National Opinion Research Center$6,258,023
Research focus
PerceptionPharmaceutical PreparationsResponseMichiganResearch PersonnelUniversitiesDecision AidDatabasesDecision MakingComplexAdverse EventBig DataBlindnessAdherenceClinical PracticeCountryCaringCare ProvidersBehaviorAdrenal Cortex HormonesBeliefClinical Trials DesignBenefits And RisksBase
Grant awards (7)
Central nervous system mechanisms and treatment response in chronic ocular surface pain$464,123
R01 · FY2025 · EY · contact PI
Central nervous system mechanisms and treatment response in chronic ocular surface pain$578,123
R01 · FY2024 · EY · contact PI
Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis$207,609
K23 · FY2022 · EY · contact PI
Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis$207,609
K23 · FY2021 · EY · contact PI
Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis$207,609
K23 · FY2020 · EY · contact PI
Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis$207,609
K23 · FY2019 · EY · contact PI
Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis$207,609
K23 · FY2018 · EY · contact PI